COVID-19
Conditions
Brief summary
This is a randomized, double blind, two arms, placebo controlled, clinical trial to study to evaluate the the safety and efficacy of Mycobacterium w in combination with standard of care versus placebo with standard of care for preventing the progression of COVID-19 disease and for reduction in transfer to ICU in COVID-19 infected patients admitted to the hospital.
Detailed description
Total 480 hospitalized adult eligible patients will be randomized in 1:1 ratio to receive either Mw+SOC or placebo+SOC for first 3 days post-randomization. Daily clinical evaluation of patient will be performed till discharge from hospital or till ICU admission. Study duration for each patient will be approximately up to 28 days, or discharge from hospital or transfer to ICU, whichever is earlier.
Interventions
Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
OTHERPlacebo
Placebo along with Standard of care (SOC) treatment for COVID-19
Sponsors
Council of Scientific and Industrial Research, India
Cadila Pharnmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
A randomized, double-blinded, two arms, placebo controlled, clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* COVID-19 positive patients with ordinal scale score of 3. * Patients of either gender, age ≥ 18 years at the time of enrollment. * Female patients who are currently using reliable methods of contraception (barrier methods and intrauterine contraceptive device), with a negative urine pregnancy test during screening and agree to informed compliance of contraceptive method until at least 3 months post-dosing. * The patients must be able and willing to comply with the study protocol, available and willing to complete all the study assessments and must have signed an Informed Consent Form.
Exclusion criteria
* Patient with ordinal scale of ≥4 at the time of hospital admission and randomization. * Pregnant and / or lactating female patients. * A family history of congenital or hereditary immunodeficiency. * Any disease condition requiring ICU admission. * History of dialysis, silicosis, solid organ transplantation such as renal or cardiac transplants, and disorders of the heart, or nervous system, or other metabolic inflammatory conditions, psychiatric, occupational problems that make it unlikely that the patients will comply with the protocol as determined by the investigator. * History of administration of any immunoglobulins, any immunotherapy (antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, and corticosteroids use) and/or any blood products within the 3 months preceding study dosing, or planned future administrations during the study period. * History of allergic reactions or anaphylaxis to Mw or its component. * Presence of any severe systemic/autoimmune disorders as determined by medical history and/or physical examination at the time of screening, which in the judgment of the Investigator would compromise the patient's health or is likely to result nonconformance to the protocol or a patient's ability to give written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with increased disease severity | From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing. | To compare the difference in proportion of patients with increased disease severity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events and serious adverse events (Safety) | Till day 28 | To evaluate safety of Mw in COVID-19 patients admitted to hospital |
| Number of COVID-19 patients discharged from hospital | From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing. | To compare the proportion of patients discharged from hospital |
| Number of COVID-19 patients transfer to ICU | From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing. | To compare the proportion of patients transfer to ICU |
| Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale | From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing. | To compare the proportion of patients with reduction in disease severity by 1 ordinal scale |
| Number of of symptom free patients | From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing. | To compare the proportion of symptom free patients |
Countries
India
Contacts
Primary ContactAnil Avhad, MBBS
Backup ContactAshish Amarsheda
Outcome results
None listed